Cargando…

Oncometabolites suppress DNA repair by disrupting local chromatin signaling

Deregulation of metabolism and disruption of genome integrity are hallmarks of cancer1. Elevated levels of the metabolites, 2-hydroxyglutarate (2HG), succinate, and fumarate, occur in human malignancies due to somatic mutations in the isocitrate dehydrogenase-1/2 (IDH1/2) genes or germline mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulkowski, Parker L., Oeck, Sebastian, Dow, Jonathan, Economos, Nicholas G., Mirfakhraie, Lily, Liu, Yanfeng, Noronha, Katelyn, Bao, Xun, Li, Jing, Shuch, Brian M., King, Megan C., Bindra, Ranjit S., Glazer, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319896/
https://www.ncbi.nlm.nih.gov/pubmed/32494005
http://dx.doi.org/10.1038/s41586-020-2363-0
_version_ 1783551135283412992
author Sulkowski, Parker L.
Oeck, Sebastian
Dow, Jonathan
Economos, Nicholas G.
Mirfakhraie, Lily
Liu, Yanfeng
Noronha, Katelyn
Bao, Xun
Li, Jing
Shuch, Brian M.
King, Megan C.
Bindra, Ranjit S.
Glazer, Peter M.
author_facet Sulkowski, Parker L.
Oeck, Sebastian
Dow, Jonathan
Economos, Nicholas G.
Mirfakhraie, Lily
Liu, Yanfeng
Noronha, Katelyn
Bao, Xun
Li, Jing
Shuch, Brian M.
King, Megan C.
Bindra, Ranjit S.
Glazer, Peter M.
author_sort Sulkowski, Parker L.
collection PubMed
description Deregulation of metabolism and disruption of genome integrity are hallmarks of cancer1. Elevated levels of the metabolites, 2-hydroxyglutarate (2HG), succinate, and fumarate, occur in human malignancies due to somatic mutations in the isocitrate dehydrogenase-1/2 (IDH1/2) genes or germline mutations in the fumarate hydratase (FH) and succinate dehydrogenase (SDH) genes, respectively(2–4). Recent work has made an unexpected connection between these metabolites and DNA repair by showing that they suppress the pathway of homology-dependent repair (HDR)(5,6) and confer an exquisite sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors that is being tested in clinical trials. However, the mechanism by which these oncometabolites inhibit HDR remains poorly understood. Here we elucidate the pathway by which these metabolites disrupt DNA repair. We show that oncometabolite-induced inhibition of the lysine demethylase KDM4B results in aberrant hypermethylation of histone 3 lysine 9 (H3K9) at loci surrounding DNA breaks, masking a local H3K9 trimethylation signal that is essential for the proper execution of HDR. Consequently, recruitment of Tip60 and ATM, two key proximal HDR factors, is significantly impaired at DNA breaks, with reduced end-resection and diminished recruitment of downstream repair factors. These findings provide a mechanistic basis for oncometabolite-induced HDR suppression and may guide effective strategies to exploit these defects for therapeutic gain.
format Online
Article
Text
id pubmed-7319896
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-73198962020-12-03 Oncometabolites suppress DNA repair by disrupting local chromatin signaling Sulkowski, Parker L. Oeck, Sebastian Dow, Jonathan Economos, Nicholas G. Mirfakhraie, Lily Liu, Yanfeng Noronha, Katelyn Bao, Xun Li, Jing Shuch, Brian M. King, Megan C. Bindra, Ranjit S. Glazer, Peter M. Nature Article Deregulation of metabolism and disruption of genome integrity are hallmarks of cancer1. Elevated levels of the metabolites, 2-hydroxyglutarate (2HG), succinate, and fumarate, occur in human malignancies due to somatic mutations in the isocitrate dehydrogenase-1/2 (IDH1/2) genes or germline mutations in the fumarate hydratase (FH) and succinate dehydrogenase (SDH) genes, respectively(2–4). Recent work has made an unexpected connection between these metabolites and DNA repair by showing that they suppress the pathway of homology-dependent repair (HDR)(5,6) and confer an exquisite sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors that is being tested in clinical trials. However, the mechanism by which these oncometabolites inhibit HDR remains poorly understood. Here we elucidate the pathway by which these metabolites disrupt DNA repair. We show that oncometabolite-induced inhibition of the lysine demethylase KDM4B results in aberrant hypermethylation of histone 3 lysine 9 (H3K9) at loci surrounding DNA breaks, masking a local H3K9 trimethylation signal that is essential for the proper execution of HDR. Consequently, recruitment of Tip60 and ATM, two key proximal HDR factors, is significantly impaired at DNA breaks, with reduced end-resection and diminished recruitment of downstream repair factors. These findings provide a mechanistic basis for oncometabolite-induced HDR suppression and may guide effective strategies to exploit these defects for therapeutic gain. 2020-06-03 2020-06 /pmc/articles/PMC7319896/ /pubmed/32494005 http://dx.doi.org/10.1038/s41586-020-2363-0 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Sulkowski, Parker L.
Oeck, Sebastian
Dow, Jonathan
Economos, Nicholas G.
Mirfakhraie, Lily
Liu, Yanfeng
Noronha, Katelyn
Bao, Xun
Li, Jing
Shuch, Brian M.
King, Megan C.
Bindra, Ranjit S.
Glazer, Peter M.
Oncometabolites suppress DNA repair by disrupting local chromatin signaling
title Oncometabolites suppress DNA repair by disrupting local chromatin signaling
title_full Oncometabolites suppress DNA repair by disrupting local chromatin signaling
title_fullStr Oncometabolites suppress DNA repair by disrupting local chromatin signaling
title_full_unstemmed Oncometabolites suppress DNA repair by disrupting local chromatin signaling
title_short Oncometabolites suppress DNA repair by disrupting local chromatin signaling
title_sort oncometabolites suppress dna repair by disrupting local chromatin signaling
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319896/
https://www.ncbi.nlm.nih.gov/pubmed/32494005
http://dx.doi.org/10.1038/s41586-020-2363-0
work_keys_str_mv AT sulkowskiparkerl oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT oecksebastian oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT dowjonathan oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT economosnicholasg oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT mirfakhraielily oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT liuyanfeng oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT noronhakatelyn oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT baoxun oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT lijing oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT shuchbrianm oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT kingmeganc oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT bindraranjits oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling
AT glazerpeterm oncometabolitessuppressdnarepairbydisruptinglocalchromatinsignaling